No. 27 (2019), Resumos
No. 27 (2019)

Reduction of biologics in rheumatoid arthritis: a living systematic review and meta-analysis

Resumos
Published 2019-12-20
Leticia Breda e Vasconcelos
Universidade Estadual de Campinas
Tais Galvao
Universidade Estadual de Campinas
https://orcid.org/0000-0003-2072-4834
PDF (Portuguese)

Keywords

Rheumatoid arthritis
Biologics
Dose reduction

How to Cite

VASCONCELOS, Leticia Breda e; GALVAO, Tais. Reduction of biologics in rheumatoid arthritis: a living systematic review and meta-analysis. Revista dos Trabalhos de Iniciação Científica da UNICAMP, Campinas, SP, n. 27, p. 1–1, 2019. DOI: 10.20396/revpibic2720192101. Disponível em: https://econtents.sbu.unicamp.br/eventos/index.php/pibic/article/view/2101. Acesso em: 22 apr. 2026.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

This living systematic review assesses the effectiveness and safety of reducing or spacing the dose of biological drugs in patients with rheumatoid arthritis at low disease activity, compared to standard dose treatment. Clinical outcomes data were collected and summarized in meta-analysis of standardized mean difference or relative risk. Most outcomes were non-significant.

PDF (Portuguese)

References

Van Herwaarden, Noortje et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev, 2014;29(9):CD010455.

Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-26.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2019 Revista dos Trabalhos de Iniciação Científica da UNICAMP